A New Era in Early Autism Support: LinusBio and Autism Speaks Partner to Promote Earlier Autism Diagnosis and Intervention
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Apr 17, 2025--
LinusBio, a leader in precision exposome medicine, and Autism Speaks, the leading research and advocacy organization dedicated to supporting the autism community, today announced a partnership to advance early autism diagnosis and intervention. As part of the collaboration, Autism Speaks will provide educational materials and resources to families concerned about autism, helping them better understand the potential of biomarker testing for earlier detection. To further support accessibility, Autism Speaks will also offer ClearStrand-ASD — LinusBio's innovative biomarker test — at a reduced cost to families in need. LinusBio will additionally support Autism Speaks' ongoing community initiatives.
This joint effort will directly power two major Autism Speaks initiatives: The first is the Autism Response Team (ART) — Autism Speaks' frontline support system that connects the autism community to trusted information and resources. Through this partnership, ART will share educational materials about ClearStrand-ASD and provide exclusive discount codes, helping families access the latest advancements in biomarker testing for autism. The second initiative is the Empower Summit & Challenge — a series of two-day events launching this spring in five U.S. cities. These events bring together autistic individuals, families, service providers, and policymakers to address some of the most pressing issues facing the community. At each summit, LinusBio will host an interactive space within the resource fair, offering families a hands-on opportunity to learn more about the cutting-edge science behind ClearStrand-ASD and how it may support earlier diagnosis and intervention.
'Autism Speaks is the leading organization in the U.S. focused on research and advocacy to support the autism community, and we are proud to partner with them to advance improved outcomes through innovation,' said Dr. Manish Arora, founder and CEO at LinusBio. 'Together, we aim not only to raise awareness among families, healthcare providers, and clinicians about the benefits of biomarker testing for autism — and how it can support earlier diagnosis and intervention — but also to make a tangible, immediate impact for families currently seeking answers.'
Early diagnosis and interventions are key to better long-term outcomes, but many families still encounter lengthy delays in accessing the diagnostic support they need. ClearStrand-ASD offers a powerful new tool to support healthcare providers and caregivers during a critical window — ages 1 month to 36 months — when early intervention may be most effective. This partnership marks a major milestone in connecting families to essential healthcare resources when they need them most.
'At Autism Speaks, we're committed to supporting innovative research that could lead to earlier identification and more personalized care for people with autism,' said Dr. Andy Shih, Chief Science Officer at Autism Speaks. 'Our collaboration with LinusBio is focused on evaluating a promising diagnostic technology through rigorous, community-based research. By supporting participation of patients and their families through educational information from our Autism Response Team, we hope to ensure the tool could benefit a large and diverse population so that it may one day improve access to earlier diagnosis for families in need.'
'For most of my life, I was misdiagnosed or dismissed. Getting an autism diagnosis as an adult finally gave me the answers I had been searching for,' said Victoria Handy, an Autism Speaks Champion of Change. 'That experience changed how I see myself — and how I support my daughter, who is also autistic. Every family deserves the chance to understand sooner. That's why partnerships like this one matter. Tools like ClearStrand-ASD can give parents a head start on what I didn't have: answers early enough to truly help make a difference.'
ClearStrand-ASD must be ordered by a licensed health care provider. LinusBio enables caregivers to request the test from home through an independent telehealth provider. The test is intended for infants and toddlers who are at an elevated risk of autism, such as those who were born preterm, who have a sibling with autism, or who have demonstrated characteristics associated with autism. If the test does not detect the biomarker, it is unlikely the child has autism. If the test does find the biomarker, the child may need further professional evaluation. ClearStrand-ASD now available at www.clearstrandasd.com.
About LinusBio
LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in North Brunswick, NJ. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. For more information, visit www.linusbio.com.
About Autism Speaks
Autism Speaks is dedicated to creating an inclusive world for all individuals with autism throughout their lifespan. In response to the pressing needs of the 1 in 31 children and 1 in 45 adults with autism in the U.S. today, Autism Speaks provides resources and tools for autistic individuals of all ages and levels of support. Connecting millions of people with autism and their families to free services, supports, research, innovation and advances in care, the nonprofit serves as a convener for the autism community with the goal of making a real difference for all people on the autism spectrum. Learn more and join the movement by following @AutismSpeaks on social media.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250417662415/en/
CONTACT: Media Contact:
LinusBio
Rachel Ford Hutman
[email protected]
301-801-5540
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: HEALTH NEUROLOGY OTHER SCIENCE RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Linus Biotechnology Inc.
Copyright Business Wire 2025.
PUB: 04/17/2025 08:25 AM/DISC: 04/17/2025 08:25 AM
http://www.businesswire.com/news/home/20250417662415/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Increased Toxicity Risk Identified For Children With ADHD, Autism
The number of people being diagnosed with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) has risen sharply in recent decades, and research continues to look at factors involved in these conditions. A study published in 2023 revealed there's a difference in how children with autism or ADHD clear the common plastic compound bisphenol A (BPA), compared to neurotypical children. BPA is used in a lot of plastics and plastic production processes, and can also be found inside food and drink cans. However, previous research has also linked it to health issues involving hormone disruption, including breast cancer and infertility. Researchers from Rowan University and Rutgers University in the US looked at three groups of children: 66 with autism, 46 with ADHD, and 37 neurotypical kids. In particular, they analyzed the process of glucuronidation, a chemical process the body uses to clear out toxins within the blood through urine. They found that kids with ASD and ADHD couldn't clear out BPA and another similar compound called diethylhexyl phthalate (DEHP) with as much efficiency as other kids, potentially leading to longer exposure to their toxic effects. "Detoxification of these two plasticizers is compromised in children with ASD and ADHD," wrote the researchers in their published paper. "Consequently, their tissues are more exposed to these two plasticizers." It was only in the case of BPA that the difference was statistically significant though: the efficiency was reduced by about 11 percent for kids with ASD and 17 percent for kids with ADHD, compared with the control group of children. The researchers think that gene mutations in certain individuals mean that BPA can't be cleared as well as it needs to be, which means the substance sticks around in the body. That potentially could cause damage in terms of neuron development and operation. Conditions like ASD and ADHD are thought to involve a combination of genetic and environmental influences, and this new study brings together both of them. However, it's only part of the story – not every child with a neurodevelopmental disorder had problems flushing out BPA, so there are other factors at play, too. Work is continuing to identify how exactly ASD and ADHD develop in people – whether it's in utero before birth for example, or later on in life – as the data isn't enough to show whether BPA exposure causes either disorder. "There is an extensive body of epidemiological evidence for a relationship between neurodevelopmental disorders and environmental pollutants such as plasticizers," the researchers wrote. "How important plasticizer originated neurodevelopmental disorder is in the overall occurrence of these disorders is not known, but it must account for a significant proportion or would not have been so easy to detect in a metabolic study of moderate size such as this study." The research was published in PLOS ONE. A version of this article was first published in October 2023. Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover Texas Woman Dies From Brain-Eating Amoeba After Flushing Sinuses Menopause Drug Reduces Breast Cancer Growth In Clinical Trial
Business Wire
3 days ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in California
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in California, making it available across 48 states in the US. This expansion marks a significant step in LinusBio's mission to enable earlier identification of autism spectrum disorder (ASD) and support early intervention. "Every parent deserves answers, and they deserve them as early as possible." - Dr. Manish Arora, Founder and CEO of LinusBio Share ClearStrand-ASD leverages proprietary robotics and lasers to analyze a strand of hair to identify biological and molecular patterns indicative of ASD. The result is an objective, noninvasive screening tool that supports clinical decision-making during a child's most critical window of development. 'ClearStrand-ASD was developed to address one of the greatest challenges families face when concerned about autism: the uncertainty and waiting. Every parent deserves answers, and they deserve them as early as possible. We know that early detection and timely intervention can profoundly shape a child's future. Whether ClearStrand-ASD helps rule out autism or prompts earlier action, what we're ultimately giving families is something invaluable — time. Time to plan, to act, and to hope. We're deeply honored to offer this breakthrough to families and providers in California,' said Dr. Manish Arora, Founder and CEO of LinusBio. 'Our goal is to empower clinicians with more objective, personalized insights so they can better support the children and families who need it most.' In a state as diverse as California, where children's backgrounds, resources, and care pathways can vary widely, early intervention can be the difference between delayed development and long-term success. Yet, many families face long waitlists or lack of access to diagnostic services altogether. Dr. Tanya Altmann, a nationally recognized pediatrician and author, has used ClearStrand-ASD at her Calabasas practice as part of a more comprehensive approach to developmental care. 'In pediatrics, time matters. The earlier we can identify potential concerns, the sooner we can intervene, and early intervention can make a lifelong difference,' said Dr. Altmann. 'ClearStrand-ASD gives me an additional layer of insight, especially when families have concerns but don't yet have a diagnosis. Its high predictive value in ruling out autism is an important factor when discussing next steps with parents, and it can be incredibly helpful in prioritizing which children need further evaluation. It's a powerful tool to help guide next steps in care and give parents and clinicians an early indicator they can act on.' LinusBio currently enables caregivers to request the test from home through an independent telehealth provider. With this expansion, the company is also partnering with pediatric practices, developmental specialists, and early intervention networks across California to broaden access to the test in clinical and community settings. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in North Brunswick, NJ. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. For more information, visit
Medscape
4 days ago
- Medscape
Tracking Triptan Safety During Pregnancy
Prenatal exposure to triptans, alone or with other migraine medications, was not associated with a significantly increased risk for neurodevelopmental disorders (NDDs) in children born to mothers with a history of migraine in a new study. METHODOLOGY: Researchers conducted a registry-based cohort study in Norway, using data from multiple national health registries between 2008 and 2023. The study included more than 26,000 children born to mothers with migraine, with the children followed up to 14 years of age. Among the mothers, 81% used triptans and 19% did not. Prenatal exposure to triptans and other antimigraine medications was determined by prescription fills from 12 months before pregnancy until delivery. Exposure was grouped as low use (42%), short-term low use (31%), moderate use (21%), and high use (6%). The primary outcome was diagnosis in the children of a composite of any NDD, including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and language or speech disorders. TAKEAWAY: Among the 4% of children who developed an NDD during the study, ADHD was the most common condition. Children with any prenatal exposure to triptans had a slight but not substantial increased risk for NDD compared with those with no exposure (low use weighted hazard ratio [wHR], 1.08; short-term low use wHR, 1.05; moderate use wHR, 1.09; high use wHR, 1.16). These risks decreased to null when the comparator was in low use (wHR range, 0.94-1.01). A slightly increased risk for ASD was observed in children with moderate and high exposure to triptans (wHRs, 1.24 and 1.30, respectively), but the weighted risk differences were less than 1%. The probability of exposure to other antimigraine medications was less than 10%. Prenatal exposure to co-medications was not significantly associated with the composite NDD outcome. IN PRACTICE: 'These results are encouraging for people with migraine, who may be taking these drugs before they even know that they are pregnant, and this is helpful information for their physicians, who can make more informed decisions about treating people with debilitating migraine attacks,' study investigator Hedvig Nordeng, PhD, University of Oslo, Oslo, Norway, said in a press release. SOURCE: The study was led by Margherita Camanni, University of Milano-Bicocca, Milan, Italy. It was published online on May 21 in Neurology . LIMITATIONS: The study relied on filled prescriptions instead of verified medication intake, potentially leading to exposure misclassification. The researchers could not assess the risk for specific NDDs in children after prenatal exposure to combined migraine treatments and individual triptans because of small sample sizes. Additionally, the study could not verify whether medication discontinuation at the last menstrual period was due to lower migraine severity. The possibility of live birth bias and confounding by other treatment indications could not be eliminated. DISCLOSURES: Camanni reported receiving a visiting scholarship from the Norwegian Research Council for this study. The other investigators reported no relevant conflicts of interest.
